SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
SeaStar Medical reported 2025 financial results highlighting significant progress in clinical trials for its Selective Cytopheretic Device (SCD) therapy for Acute Kidney Injury (AKI), expanding the QUELIMMUNE therapy's adoption in top pediatric hospitals, and preparing for FDA approvals. The company achieved over 50% enrollment in the pivotal NEUTR…